Literature DB >> 22348268

Eisenmenger syndrome: not always inoperable.

Jing-Bin Huang1, Jian Liang, Li-Yan Zhou.   

Abstract

Recently, advanced therapies for pulmonary arterial hypertension have become available, and have been effective in reducing pulmonary vascular resistance and symptoms in patients with Eisenmenger syndrome, previously thought to be inoperable. This review summarizes the current knowledge on the pathophysiology and treatment of Eisenmenger syndrome. The recent introduction of targeted therapies in pulmonary arterial hypertension has led to a renewed insight in the pathophysiology and treatment of Eisenmenger syndrome. Patients with Eisenmenger syndrome using a diagnostic-treatment-and-repair strategy are amenable to surgery after successful treatment with advanced therapy. With continued improvements in the diagnosis, preoperative management, refinement of surgical techniques and intra- and postoperative management strategies, the patients with Eisenmenger syndrome selected using a diagnostic-treatment-and-repair strategy are operable with safety and efficacy in the current era with advanced pulmonary arterial hypertension therapy. Future directions of Eisenmenger syndrome may be the combination of reversal of pulmonary vascular remodeling and correction. Copyright 2012 Daedalus Enterprises

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22348268     DOI: 10.4187/respcare.01418

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

Review 1.  Epigenetics: novel mechanism of pulmonary hypertension.

Authors:  Jing-bin Huang; Jian Liang; Xiao-fang Zhao; Wen-sen Wu; Fu Zhang
Journal:  Lung       Date:  2013-09-20       Impact factor: 2.584

2.  Clinical comparative analysis of histidine-tryptophan-ketoglutarate solution and St. Thomas crystalloid cardioplegia: A 12-year study from a single institution.

Authors:  Ying-Zhong Lin; Jing-Bin Huang; Xiang-Wei Li; Xian-Ming Tang; Wei-Jun Lu; Zhao-Ke Wen; Jian Liang; Dian-Yuan Li; Hao Wang
Journal:  Exp Ther Med       Date:  2017-07-19       Impact factor: 2.447

3.  Tailored circulatory intervention in adults with pulmonary hypertension due to congenital heart disease.

Authors:  L E Couperus; I R Henkens; M R M Jongbloed; M G Hazekamp; M J Schalij; H W Vliegen
Journal:  Neth Heart J       Date:  2016-04-20       Impact factor: 2.380

4.  Voice hoarseness in a patient with underlying Eisenmenger's syndrome: a case report.

Authors:  Palak Suryavanshi; Sreejit Parameswaran; Nishant Sharma; Russell A Murphy; Anil R Sharma
Journal:  J Otolaryngol Head Neck Surg       Date:  2019-08-19

5.  Transcatheter closure for patent ductus arteriosus in patients with Eisenmenger syndrome: to do or not?

Authors:  Jing Xu; Liang Wang; Yunli Shen; Liang Geng; Fadong Chen
Journal:  BMC Cardiovasc Disord       Date:  2020-12-01       Impact factor: 2.298

6.  Histidine-tryptophan-ketoglutarate solution decreases mortality and morbidity in high-risk patients with severe pulmonary arterial hypertension associated with complex congenital heart disease: an 11-year experience from a single institution.

Authors:  X W Li; Y Z Lin; H Lin; J B Huang; X M Tang; X M Long; W J Lu; Z K Wen; J Liang; D Y Li; X F Zhao
Journal:  Braz J Med Biol Res       Date:  2016-05-13       Impact factor: 2.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.